Barclays’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-118,702
| Closed | -$1.07M | – | 5470 |
|
|
2025
Q4 | $1.07M | Buy |
118,702
+116,876
| +6,401% | +$873K | ﹤0.01% | 3381 |
|
|
2025
Q3 | $5.68K | Sell |
1,826
-103,571
| -98% | -$274K | ﹤0.01% | 5072 |
|
|
2025
Q2 | $226K | Buy |
105,397
+44,034
| +72% | +$71.1K | ﹤0.01% | 4198 |
|
|
2025
Q1 | $70.6K | Sell |
61,363
-30,306
| -33% | -$52K | ﹤0.01% | 4516 |
|
|
2024
Q4 | $201K | Buy |
91,669
+11,374
| +14% | +$25.8K | ﹤0.01% | 4307 |
|
|
2024
Q3 | $175K | Buy |
80,295
+58,776
| +273% | +$135K | ﹤0.01% | 4362 |
|
|
2024
Q2 | $49.7K | Sell |
21,519
-11,487
| -35% | -$47.7K | ﹤0.01% | 4215 |
|
|
2024
Q1 | $182K | Sell |
33,006
-40,258
| -55% | -$184K | ﹤0.01% | 4166 |
|
|
2023
Q4 | $181K | Sell |
73,264
-154,956
| -68% | -$1.47M | ﹤0.01% | 4462 |
|
|
2023
Q3 | $7.93M | Buy |
228,220
+204,762
| +873% | +$7.08M | ﹤0.01% | 1097 |
|
|
2023
Q2 | $769K | Buy |
23,458
+5,954
| +34% | +$205K | ﹤0.01% | 2486 |
|
|
2023
Q1 | $586K | Buy |
17,504
+6,669
| +62% | +$259K | ﹤0.01% | 3159 |
|
|
2022
Q4 | $355K | Buy |
10,835
+7,787
| +255% | +$231K | ﹤0.01% | 3522 |
|
|
2022
Q3 | $106K | Sell |
3,048
-275,335
| -99% | -$6.1M | ﹤0.01% | 3526 |
|
|
2022
Q2 | $3.41M | Sell |
278,383
-10,657
| -4% | -$159K | ﹤0.01% | 1525 |
|
|
2022
Q1 | $3.92M | Buy |
+289,040
| New | +$3.86M | ﹤0.01% | 1377 |
|
Other funds holding VTYX
Barclays's VTYX Position: Q1 2026 in Review
Barclays sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 118,702 shares — an estimated $1.07M sold.
Barclays first reported a position in VTYX in Q1 2022 and held it in 16 quarters. The position peaked at $7.93M in Q3 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Barclays reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Barclays sold 118,702 Ventyx Biosciences shares in Q1 2026, an estimated $1.07M.
- Barclays first reported a position in Ventyx Biosciences in Q1 2022 and held it in 16 quarters.
- Barclays's Ventyx Biosciences position peaked at $7.93M in Q3 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.